Target intelligence / Profile preview

Type IV pilin subunit PilA (PilA)

Target
PilA
Molecular classification
Bacterial surface protein, Adhesin, Structural protein, Pilin
01

Overview

PilA is the major structural subunit of Type IV pili (Tfp) in non-typeable Haemophilus influenzae (NTHi), a Gram-negative bacterium that is a common commensal of the human nasopharynx but also a significant opportunistic pathogen (Novotny et al., 2015). Tfp are hair-like appendages on the bacterial surface that play critical roles in adherence to host respiratory epithelial cells, twitching motility, natural transformation (competence), and the formation and stability of biofilms (Jurcisek et al., 2007; Bakaletz, 2018). In the context of disease, NTHi is a leading cause of acute otitis media in children and acute exacerbations of chronic obstructive pulmonary disease (COPD) in adults (Wilkinson et al., 2022). PilA is a primary target for therapeutic intervention, particularly as a vaccine candidate, because it is highly conserved across NTHi strains and essential for colonization and persistence (Novotny et al., 2015). Experimental vaccines using recombinant soluble PilA (rsPilA) or fusion proteins (such as PE-PilA) have shown the ability to elicit antibodies that not only prevent NTHi adherence but also actively disperse established biofilms, thereby increasing the susceptibility of the bacteria to host immune defenses and traditional antibiotics (Bakaletz, 2018; Wilkinson et al., 2022). The development of PilA-targeted therapies represents a promising strategy to reduce the burden of chronic and recurrent respiratory infections caused by NTHi (Novotny et al., 2015).

Other names
Major pilin subunitType IV pilinrsPilARecombinant soluble PilA
02

Mechanism of action

Induction of antibodies that inhibit bacterial adherence to host cells and promote the dispersal of bacterial biofilms

03

Biological functions

Bacterial adherenceBiofilm formationTwitching motilityNatural transformationBacterial colonization
04

Disease associations

InfectionOtitis mediaChronic obstructive pulmonary diseaseSinusitisBronchitis
05

Safety considerations

Antigenic variation among strainsBiofilm-mediated therapeutic resistanceStrain-specific efficacy
06

Interacting drugs

NTHi-Mcat vaccine

2 more in the full profile.

07

Biomarkers

Anti-PilA IgG antibody titer

Beyond the preview

Go deeper on Type IV pilin subunit PilA (PilA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Type IV pilin subunit PilA (PilA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call